Using baseline MRI radiomic features to predict the efficacy of repetitive transcranial magnetic stimulation in Alzheimer's patients
- PMID: 40335871
- DOI: 10.1007/s11517-025-03366-2
Using baseline MRI radiomic features to predict the efficacy of repetitive transcranial magnetic stimulation in Alzheimer's patients
Abstract
The efficacy of repetitive transcranial magnetic stimulation (rTMS) as a treatment for Alzheimer's disease (AD) is uncertain at baseline. Herein, we aimed to investigate whether radiomic features from the pre-treatment MRI data could predict rTMS efficacy for AD treatment. Out of 110 participants with AD in the active (n = 75) and sham (n = 35) rTMS treatment groups having T1-weighted brain MRI data, we had two groups of responders (active = 55 and sham = 24) and non-responders (active = 20 and sham = 11). We extracted histogram-based radiomic features from MRI data using 3D Slicer software; the most important features were selected utilizing a combination of a two-sample t-test, correlation test, least absolute shrinkage, and selection operator. The support vector machine classified rTMS responders and non-responders with a cross-validated mean accuracy/AUC of 81.9%/90.0% in the active group and 87.4%/95.8% in the sham group. Further, the radiomic features of the active group significantly correlated with participants' AD assessment scale-cognitive subscale (ADAS-Cog) change after treatment (false discovery rate corrected p < 0.05). Given that baseline radiomic features were able to accurately predict AD patients' responses to rTMS treatment, these radiomic features warrant further investigation for personalizing AD therapeutic strategies.
Keywords: Alzheimer’s disease; Efficacy prediction; Magnetic resonance imaging; Radiomic features; Repetitive transcranial magnetic stimulation.
© 2025. International Federation for Medical and Biological Engineering.
Conflict of interest statement
Declarations. Competing interests: In the last 3 years, the coauthor, P.B.F., has received equipment for research from Neurosoft and Nexstim. He has served on a scientific advisory board for Magstim and received speaker fees from Otsuka. He has also acted as a founder and board member for TMS Clinics Australia and Resonance Therapeutics. P.B.F. is supported by a National Health and Medical Research Council of Australia Investigator grant (1193596). For other authors, there is no conflict of interest.
References
-
- Koch G, Casula EP, Bonnì S et al (2022) Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial. Brain 145:3776–3786. https://doi.org/10.1093/brain/awac285 - DOI - PubMed - PMC
-
- Moussavi Z, Uehara M, Rutherford G et al (2024) Repetitive transcranial magnetic stimulation as a treatment for Alzheimer’s disease: a randomized placebo-controlled double-blind clinical trial. Neurotherapeutics 21:e00331. https://doi.org/10.1016/j.neurot.2024.e00331 - DOI - PubMed - PMC
-
- Li X, Qi G, Yu C et al (2021) Cortical plasticity is correlated with cognitive improvement in Alzheimer’s disease patients after rTMS treatment. Brain Stimul 14:503–510. https://doi.org/10.1016/j.brs.2021.01.012 - DOI - PubMed
-
- Lithgow BJ, Dastgheib Z, Moussavi Z (2022) Baseline prediction of rTMS efficacy in Alzheimer patients. Psychiatry Res 308:114348. https://doi.org/10.1016/j.psychres.2021.114348 - DOI - PubMed
-
- Saha C, Figley CR, Lithgow B et al (2024) Can brain volume-driven characteristic features predict the response of Alzheimer’s patients to repetitive transcranial magnetic stimulation? A pilot study Brain Sci 14:226. https://doi.org/10.3390/brainsci14030226 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
